VolitionRX Innovates Cancer Detection with Capture-Seq™ and Advances Sepsis Diagnostics

### VolitionRX Advances Cancer Detection Through Innovative Technology

VolitionRX Limited, a multinational epigenetics firm headquartered in Henderson, Nevada, is making remarkable strides in cancer detection with its innovative Capture-Seq™ platform, recently submitted for peer review. This technology opens up a vast potential market for early cancer detection, estimated at $23 billion annually. Capture-Seq™ allows for the direct analysis of transcription factor protected circulating free DNA (cfDNA) in plasma, which can significantly enhance the accuracy and efficiency of cancer diagnostics. With the rising prevalence of cancer globally, VolitionRX positions itself at the forefront of a critical industry, aiming to provide low-cost and precise testing solutions that can greatly improve patient outcomes.

In its effort to bring innovative cancer detection methods to market, VolitionRX is actively advancing its Nu.Q® Cancer assays. The company is currently navigating a reimbursement application process in France, with plans to implement routine clinical use for lung cancer by the fourth quarter of 2026. This initiative is bolstered by collaboration with France's second-largest hospital system, emphasizing the growing recognition of VolitionRX's technology within the healthcare community. The successful launch of these tests could fundamentally transform how lung cancer is diagnosed and managed, ultimately impacting patient care on a larger scale.

In addition to its cancer detection advancements, VolitionRX is making significant contributions to sepsis diagnostics. The company's Nu.Q® NETs assay is part of the government-backed DETECSEPS initiative in France, which is funded at approximately $7.3 million. This program prioritizes early detection and tailored treatment of sepsis, a condition that poses great challenges in emergency medicine. By incorporating its innovative technology into such critical health initiatives, VolitionRX not only showcases its potential but also reinforces its commitment to addressing pressing medical needs.

VolitionRX's recent accomplishments extend beyond specific tests to establishing meaningful partnerships that can advance the commercialization of its technologies. The company is currently engaged in discussions with approximately ten leading global diagnostic firms, aiming to leverage their extensive networks and expertise for more effective technology deployment. By actively pursuing strategic collaborations, VolitionRX seeks to enhance its market presence and ensure that its groundbreaking cancer detection methods are accessible to a broader patient population, thereby fostering advancements in public health.